Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Monday, 17 July 2017

ABLYNX PROPOSES APPOINTMENT OF MRS HILDE WINDELS AS A NEW INDEPENDENT DIRECTOR

Ablynx    

ABLYNX PROPOSES APPOINTMENT OF MRS HILDE WINDELS AS A NEW INDEPENDENT DIRECTOR

GHENT, Belgium, 17 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that Hilde Windels will be nominated as an Independent Non-Executive Director at the Company's forthcoming Special General Meeting of its shareholders to be held on 18 August 2017.

 

Mrs. Windels is currently CEO ad interim of Biocartis NV and a member of the Board of Biocartis NV, Biocartis Group NV, Erytech Pharma SA and Vlaams Instituut voor Biotechnologie (VIB). She has approximately 20 years of experience in the biotechnology field with a track record of building and structuring organisations, private fundraising, M&A, capital markets and business and corporate strategy. Mrs. Windels served as CFO for Biocartis NV from 2011 until she became Deputy CEO in 2015. From 2009 to 2011, she worked as an independent CFO for several private biotech companies. From 1999 to 2008, Mrs. Windels was CFO and a board member of Devgen NV.

 

Welcoming Mrs. Windels to the Ablynx Board, Dr Peter Fellner, Chairman, said: "We are very pleased with the proposed forthcoming appointment of Hilde Windels to the Ablynx Board. Hilde's broad industry experience as well as her impressive financial expertise will help guide the Company as we continue to build value in terms of both our proprietary product pipeline and strategic collaborations with pharmaceutical companies using our Nanobody platform."

 

Commenting on her appointment, Mrs. Windels added: "I am delighted to become part of Ablynx's Board and contribute to the Company's future development. Ablynx has ambitions to become a vertically integrated pharmaceutical company and I look forward to contributing to this exciting journey."

 

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

 

For more information, please contact

Ablynx:

Dr Edwin Moses

CEO

t:   +32 (0)9 262 00 07

m: +32 (0)473 39 50 68

e:  edwin.moses@ablynx.com

 

Lies Vanneste

Director Investor Relations

t:   +32 (0)9 262 01 37

m: +32 (0)498 05 35 79

e:  lies.vanneste@ablynx.com

 

Follow us on Twitter @AblynxABLX

 

 

Ablynx media/analyst relations

FTI Consulting:

Julia Phillips, Brett Pollard, Mo Noonan

t: +44 20 3727 1000

e: ablynx@fticonsulting.com

 




pdf version of press release



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Ablynx, Technologiepark 21, Ghent/Zwijnaarde 9052, België
If you would like to unsubscribe and stop receiving these e-mails click here.